Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.41 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.41 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884976 | 1.00 | MEN1 (0.46) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6884952 | 0.79 | MAPT (0.68) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6885982 | 0.79 | MAPT (0.48) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6885985 | 0.79 | MAPT (0.48) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6881144 | 0.78 | MAPT (0.56) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6881148 | 0.78 | MAPT (0.56) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6883752 | 0.78 | MAPT (0.53) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6883748 | 0.78 | MAPT (0.53) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6882967 | 0.76 | PTPN1 (0.55) | MEN1HPGDKMT2APOLBALOX12 | |
| SCHEMBL6882963 | 0.76 | PTPN1 (0.55) | MEN1HPGDKMT2APOLBALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | MEN1 838/4885HPGD 1203/4885KMT2A 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.